Table 3.

Characteristics of participants at follow-up NT-proBNP measure, by interval change in NT-proBNP

	Baseline <190 pg/mL (N=2,243)
	>25% Decrease	No significant increase	Increase >25% and >190 pg/mL	Test For Trend
	N=357 (16%)	N=1,418 (63%)	N=468 (21%)
Age (years)	73.1 (4.0)	73.6 (4.3)	75.7 (5.0)	<0.001
Male	141 (39.5%)	552 (38.9%)	184 (39.2%)	0.98
African-American	70 (19.6%)	263 (18.6%)	42 (9.0%)	<.001
Diabetes	74 (20.7%)	237 (16.7%)	56 (12.0%)	<.001
Coronary heart disease	41 (11.5%)	198 (14.0%)	124 (26.5%)	<.001
Hypertension	158 (44.4%)	767 (54.2%)	288 (61.5%)	<.001
Major ECG abnormality	55 (21.0%)	241 (22.8%)	152 (42.7%)	<.001
BMI (kg/m2)	27.7 (4.6)	27.1 (4.5)	26.3 (4.7)	<.001
eGFR (cc/min/1.73m2)	71.0 (15.9)	70.1 (15.3)	65.7 (16.0)	<.001
Baseline NT-proBNP	89.1 [59.6, 127.6]	60.8 [33.1, 93.9]	116.1 [75.9, 148.6]	<.001
ACEI/ARB	43 (12.0%)	113 (8.0%)	52 (11.1%)	0.9
Beta blocker	23 (6.4%)	133 (9.4%)	85 (18.2%)	<.001

	Baseline ≥190 pg/mL (N=732)
	Decrease >25% and <190 pg/mL	No significant decrease	>25% Increase	Test for trend
	N=112 (15%)	N=327 (45%)	N=293 (40%)
Age (years)	75.1 (5.0)	76.6 (5.6)	78.4 (6.1)	<.001
Male	32 (28.6%)	101 (30.9%)	122 (41.6%)	.003
African-American	23 (20.5%)	36 (11.0%)	27 (9.2%)	.005
Diabetes	18 (16.1%)	32 (9.8%)	46 (15.7%)	0.51
Coronary heart disease	24 (21.4%)	86 (26.3%)	107 (36.5%)	<.001
Hypertension	78 (69.6%)	215 (65.8%)	193 (66.1%)	0.6
Major ECG abnormality	25 (28.1%)	98 (40.0%)	100 (53.5%)	<.001
BMI (kg/m2)	27.7 (5.6)	25.8 (4.6%)	25.9 (4.6)	.007
eGFR (cc/min/1.73m2)	66.3 (15.0)	63.0 (16.7)	58.7 (17.0)	<.001
Baseline NT-proBNP	251.7 [216.6, 302.4]	366.5 [247.7, 595.3]	300.6 [237.5, 474.5]	.007
ACEI/ARB	15 (13.4%)	38 (11.6%)	31 (10.6%)	0.4
Beta blocker	18 (16.1%)	51 (15.6%)	65 (22.2%)	.06

ARB, angiotensin receptor blocker; other abbreviations as in Table 1